Bipolar depression: a review of randomised clinical trials

Bibliography

• GOODWIN FK, JAMISON KR: Manic-Depressive Illness. New York & Oxford, Oxford University Press, 1990.
   Google Scholar
• STOKES PE, SHAMOIAN CA, STOLL PM, PATTON MJ: Efficacy of lithium as acute treatment of manic-depressive illness. Lancet (1971) 1:1319-1325.
   PubMed Web of Science ®Google Scholar
• TONDO L, HENNEN J, BALDESSARINI RJ: Lower suicide risk with long-term lithium treatment in major affective illness: a meta-analysis. Acta Psychiatr. Scand. (2001) 104:163-172.
   PubMed Web of Science ®Google Scholar
• GOODWIN FK, FIREMAN B, SIMON GE: Suicide risk in bipolar disorder during treatment with lithium and divalproex. JAMA (2003) 290:1467-1473.
   PubMed Web of Science ®Google Scholar
• NEMEROFF CB, EVANS DL, GYULAI L et al.: Double-blind, placebo-controlled comparison of imipramine and paroxetine in the treatment of bipolar depression. Am. J. Psychiatry (2001) 158:906-912.
   PubMed Web of Science ®Google Scholar
• POST RM, UHDE TW, ROY-BYRNE PP, JOFFE RT: Antidepressant effects of carbamazepine. Am. J. Psychiatry (1986) 143:29-34.
   PubMed Web of Science ®Google Scholar
• ZHANG ZJ, KANG WH, TAN QR: Adjunctive herbal medicine with carbamazepine for bipolar disorders: a double-blind, randomized, placebo-controlled study. J. Psychiatr. Res. (2005) Epub ahead of print.
   Google Scholar
• DAVIS LL, BARTOLUCCI A, PETTY F: Divalproex in the treatment of bipolar depression: a placebo-controlled study. J. Affect. Dis. (2005) 85:259-266.
   PubMed Web of Science ®Google Scholar
• DUNN RT, GILMER W, FLECK J et al.: Divalproex monotherapy for acute bipolar depression: a double-blind, randomized placebo-controlled trial. 159th Annual Meeting American Psychiatric Association. Toronto, Ontario, Canada (20 – 25 May 2006) NR205.
   Google Scholar
• SACHS G, ALTSHULER L, KETTER T: Divalproex versus placebo for the treatment of bipolar depression: poster presented at the American College of Neuropsychopharmacology Annual Meeting. Waikoloa, Hawaii (9 – 13 December 2001).
   Google Scholar
• CALABRESE JR, BOWDEN CL, SACHS GS, ASCHER JA, MONAGHAN E, RUDD GD: A double-blind, placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. J. Clin. Psychiatry (1999) 60:79-88.
   PubMed Web of Science ®Google Scholar
• Data on file, Lamictal, RM2002/00129/00, clinical study report for SCA40910 (2002).
   Google Scholar
• Data on file, Lamictal, RM1997/00712/00, study synopsis of SCAA2010 (603) (1999).
   Google Scholar
• Data on file, Lamictal RM2004/00533/00, study synopsis of SCA100223 (2006).
   Google Scholar
• GEDDES J, NIERENBERG A, BOURNE E et al.: Lamotrigine for acute treatment of bipolar depression: a retrospective pooled analysis of response rates in three trials. 159th Annual Meeting of the American Psychiatric Association. Toronto, Ontario, Canada (20 – 25 May 2006) NR 219.
   Google Scholar
• BROWN EB, MCELROY SL, KECK PE Jr et al.: A 7 week double-blind trial of olanzapine/fluoxetine combination versus lamotrigine in the treatment of bipolar I depression. J. Clin. Psychiatry (2006) 67(7):1025-1033.
   PubMed Web of Science ®Google Scholar
• SCHAFFER A, ZUKER P, LEVITT AJ: Randomized, double-blind pilot trial comparing lamotrigine versus citalopram for the treatment of bipolar depression. 159th Annual Meeting of the American Psychiatric Association. Toronto, Ontario, Canada (20 – 25 May 2006) NR 283.
   Google Scholar
• MCINTYRE RS, MANCINI DA, FULTON KA: Double-blind acute depression study comparing venlafaxine XR and lamotrigine when added to a mood stabilizer in the treatment of bipolar depression. Int. J. Neuropsychopharmacol. (2004) 7(Suppl. 1):S154.
   Google Scholar
• NIERENBERG AA, OSTACHER MJ, CALABRESE JR et al.: Treatment-resistant bipolar depression. A STEP-BD equipoise randomized effectiveness trial of antidepressant augmentation with lamotrigine, inositol, or risperidone. Am. J. Psychiatry (2006) 163:210-216.
   PubMed Web of Science ®Google Scholar
• MCINTYRE RS, MANCINI DA, MCCANN SM: Topiramate versus bupropion SR when added to mood stabilizer therapy for the depressive phase of bipolar disorder. A preliminary single-blind study. Bipolar Disord (2002) 4:207-213.
   PubMed Web of Science ®Google Scholar
• PRINTZ D, FLATER S, STRICKS L: A prospective, open-label study of ziprasidone augmentationj for bipolar I depression. Poster at the 24th Collegium Internationale Neuro-psychopharmacologicum. Paris, France (20 – 24 June 2004).
   Google Scholar
• DUNN RT, ZABLOTSKY B, STAN VA: Efficacy of aripiprazole in the treatment of bipolar depression. 159th Annual Meeting of the American Psychiatric Association. Toronto, Ontario, Canada (20 – 25 May 2006) NR 204.
   Google Scholar
• SHELTON RC, STAHL SM: Risperidone and paroxetine given singly and in combination for bipolar depression. J. Clin. Psychiatry (2004) 65(12):1715-1719.
   PubMed Web of Science ®Google Scholar
• TOHEN M, VIETA E, CALABRESE J: Effect of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch. Gen. Psychiatry (2003) 60(11):1079-1088.
   PubMed Web of Science ®Google Scholar
• DUNNER DL, BROWN E, ADAMS DH, DEGENHARDT E, TOHEN M, HOUSTON JP: Olanzapine/fluoxetine combination versus lamotrigine in the long-term treatment of bipolar I depression. 159th Annual Meeting of the American Psychiatric Association. Toronto, Ontario, Canada (20 – 25 May 2006) NR189.
   Google Scholar
• CALABRESE JR, KECK PE Jr, MACFADDEN W et al.: A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am. J. Psychiatry (2005) 162:1351-1360.
   PubMed Web of Science ®Google Scholar
• THASE ME, MACFADDEN W, WEISLER RH et al.: Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II study). J. Clin. Psychopharmacol. (2006) in press.
   Google Scholar
• HIRSCHFELD RM, SUPPES T, VIETA E, CARLSSON A, STENING G, MACFADDEN W: Quetiapine monotherapy is efficacious for depressive episodes in patients with bipolar II disorder. 159th Annual Meeting of the American Psychiatric Association. Toronto, Ontario, Canada (20 – 25 May 2006) NR 227.
   Google Scholar
• WEISLER R, ARVEKVIST R, STENING G, MACFADDEN W: Quetiapine monotherapy is efficacious for depressive episodes of bipolar I disorder: Combined results from two double-blind, placebo-controlled studies. 159th Annual Meeting of the American Psychiatric Association. Toronto, Ontario, Canada (20 – 25 May 2006) NR 298.
   Google Scholar
• HARDOY MC, GAROFALO A, MELLINO G, TULIGI F, CADEDDU M, CARTA MG: Quetiapine as add-on treatment for bipolar I disorder: efficacy in preventing relapse of depressive episodes. 159th Annual Meeting of the American Psychiatric Association. Toronto, Ontario, Canada (20 – 25 May 2006) NR 226.
   Google Scholar
• MATTINGLY G, LLIVICKY H, CANALE J, ANDERSON R: Quetiapine combination for treatment-resistant depression. 159th Annual Meeting of the American Psychiatric Association. Toronto, Ontario, Canada (20 – 25 May 2006) NR250.
   Google Scholar
• GHAEMI SN, ROSENQUIST KJ, KO JY, BALDASSANO CF, KONTOS NJ, BALDESSARINI RJ: Antidepressant treatment in bipolar versus unipolar depression. Am. J. Psychiatry (2004) 161:163-165.
   PubMed Web of Science ®Google Scholar
• LEVERICH GS, ALTSHULER LL, FRYE MA et al.: Risk of switch in mood polarity to hypomania or mania in patients with bipolar depression during acute and continuation trials of venlafaxine, sertraline, and bupropion as adjuncts to mood stabilizers. Am. J. Psychiatry (2006) 163:232-239.
   PubMed Web of Science ®Google Scholar
• COHN JB, COLLLINS G, ASHBROOK E, WERNICKE JF: A comparison of fluoxetine imipramine and placebo in patients with bipolar depressive disorder. Int. Clin. Psychopharmacol. (1989) 4(4):313-322.
   PubMed Web of Science ®Google Scholar
• AMSTERDAM JD, SHULTS J: Comparison of fluoxetine, olanzapine, and combined fluoxetine plus olanzapine initial therapy of bipolar Type I and Type II major depression – lack of manic induction. J. Affect. Dis. (2005) 87(1):121-130.
   PubMed Web of Science ®Google Scholar
• SVESTKA J, ZOURKOVA A, SYNEK O: Sertraline versus amitriptyline in the treatment of in-patients with acute depressive disorders. Eur. Neuropsychopharmacol. (2003) 13(Suppl. 4):S236.
   Google Scholar
• POST RM, ALTSHULER LL, LEVERICH GS et al.: Higher switch rate on venlafaxine than bupropion or sertraline in bipolar depression. Br. J. Psychiatry (2006) in press.
   PubMedGoogle Scholar
• VIETA E, MARTINEZ-ARAN A, GOIKOLEA JM et al.: A randomized trial comparing paroxetine and venlafaxine in the treatment of bipolar depressed patients taking mood stabilizers. J. Clin. Psychiatry (2002) 63:508-512.
   PubMed Web of Science ®Google Scholar
• BAUER M, ZANINELLI R, MULLER-OERLINHAUSEN B: Paroxetine and amitriptyline augmentation of lithium in the treatment of major depression: a double-blind study. J. Clin. Psychopharmacol. (1999) 19:164-171.
   PubMed Web of Science ®Google Scholar
• YOUNG LT, JOFFE RT, ROBB JC: Double-blind comparison of addition of a second mood stabilizer versus an antidepressant to an initial mood stabilizer for treatment of patients with bipolar depression. Am. J. Psychiatry (2000) 157:124-126.
   PubMed Web of Science ®Google Scholar
• SACHS GS, LAFER B, STOLL AL: A double-blind trial of bupropion versus desipramine for bipolar depression. J. Clin. Psychiatry (1994) 55:391-393.
   PubMed Web of Science ®Google Scholar
• GROSSMAN F, POTTER WZ, BROWN EA: A double-blind study comparing idazoxan and bupropion in bipolar depressed patients. J. Affect. Dis. (1999) 56:237-243.
   PubMed Web of Science ®Google Scholar
• CALABRESE JR: Issues in treating bipolar depression. 158th Meeting of American Psychiatric Association. Atlanta, GA (21 – 26 May 2005).
   Google Scholar